Drugs / SPN-821
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07226661 | Jan → Dec 2026 expected | major depressive disorder | Supernus Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPN-821 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07226661 ↗ |
| Action | Activate | “SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling” NCT07226661 ↗ |
| Route | Oral | “Three 800 mg oral tablets administered twice a week adjunctive to current antidepressant” NCT07226661 ↗ |